Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q3 2025 value amounting to 55.61%.

  • Vanda Pharmaceuticals' EBIT Margin fell 325200.0% to 55.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 57.1%, marking a year-over-year decrease of 374600.0%. This contributed to the annual value of 20.46% for FY2024, which is 132100.0% down from last year.
  • According to the latest figures from Q3 2025, Vanda Pharmaceuticals' EBIT Margin is 55.61%, which was down 325200.0% from 73.21% recorded in Q2 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' EBIT Margin peaked at 18.22% during Q2 2021, and registered a low of 81.99% during Q1 2025.
  • Moreover, its 5-year median value for EBIT Margin was 12.74% (2022), whereas its average is 13.43%.
  • As far as peak fluctuations go, Vanda Pharmaceuticals' EBIT Margin soared by 167200bps in 2021, and later plummeted by -625300bps in 2025.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' EBIT Margin stood at 12.7% in 2021, then fell by -19bps to 10.28% in 2022, then crashed by -252bps to 15.67% in 2023, then dropped by -23bps to 19.33% in 2024, then crashed by -188bps to 55.61% in 2025.
  • Its EBIT Margin was 55.61% in Q3 2025, compared to 73.21% in Q2 2025 and 81.99% in Q1 2025.